Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain

British Journal of Pharmacology

Volumn 167, Issue 3, 2012, Pages 537-547

  Ohnami, S ^a,b   Kato, A ^b   Ogawa, K ^b   Shinohara, S ^b   Ono, H ^a   Tanabe, Mitsuo ^c  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

5 HT and noradrenaline reuptake inhibitor; C fibre evoked field potential; in vivo electrophysiology; long term potentiation; neuropathic pain; spinal cord

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CAFFEINE; IDAZOXAN; METHYSERGIDE; MILNACIPRAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; YOHIMBINE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C FIBER; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; ELECTROSTIMULATION; EVOKED SPINAL CORD RESPONSE; INHIBITION KINETICS; LONG TERM POTENTIATION; LUMBAR SPINE; MALE; NERVE FIBER; NERVE LIGATION; NERVE TRANSECTION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SEROTONINERGIC SYSTEM; SPINAL CORD DORSAL HORN; SPINAL NERVE; SYNAPTIC TRANSMISSION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CYCLOPROPANES; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; EVOKED POTENTIALS; LONG-TERM POTENTIATION; MALE; NERVE FIBERS, UNMYELINATED; NEURALGIA; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SPINAL CORD; SYNAPTIC TRANSMISSION;

EID: 84866007534     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02007.x     Document Type: Article

References (66)

1. Aira Z, Buesa I, Salgueiro M, Bilbao J, Aguilera L, Zimmermann M, et al,. (2010). Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury. Neuroscience 168: 831-841.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Bardin L, Schmidt J, Alloui A, Eschalier A, (2000). Effect of intrathecal administration of serotonin in chronic pain models in rats. Eur J Pharmacol 409: 37-43.
4. Beck H, Schröck H, Sandkühler J, (1995). Controlled superfusion of the rat spinal cord for studying non-synaptic transmission: an autoradiographic analysis. J Neurosci Methods 58: 193-202.
5. Benrath J, Brechtel C, Stark J, Sandkühler J, (2005). Low dose of S(+)-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br J Anaesth 95: 518-523.
6. Bliss TV, Collingridge GL, (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39.
7. Buesa I, Urrutia A, Aira Z, Salgueiro M, Bilbao J, Mozas M, et al,. (2008). Depression of C fibre-evoked spinal field potentials by the spinal Î opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: involvement of the μ-subtype. Neuropharmacology 55: 1376-1382.
8. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al,. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880.
9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL, (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
10. Choi SS, Seo YJ, Kwon MS, Shim EJ, Lee JY, Ham YO, et al,. (2005). Increase of phosphorylation of calcium/calmodulin-dependent protein kinase-II in several brain regions by substance P administered intrathecally in mice. Brain Res Bull 65: 375-381.
11. 1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology 43: 945-958.
12. Coluzzi F, Mattia C, (2005). Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 11: 2945-2960.
13. Covey WC, Ignatowski TA, Knight PR, Spengler RN, (2000). Brain-derived TNFα: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res 859: 113-122.
14. 2 adrenoceptor subtype activated by clonidine for analgesia. Anesthesiology 97: 636-641.
15. Dziedzicka-Wasylewska M, Faron-Górecka A, Kuśmider M, Drozdowska E, RogóŻ, Siwanowicz J, et al,. (2006). Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 31: 2424-2432.
16. Fang L, Wu J, Lin Q, Willis WD, (2002). Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci 22: 4196-4204.
17. A receptor in dorsal root ganglion neurons in a rat experimental neuropathic pain model. Pain 78: 13-26.
18. Gassner M, Ruscheweyh R, Sandkühler J, (2009). Direct excitation of spinal GABAergic interneurons by noradrenaline. Pain 145: 204-210.
19. Ge YX, Xin WJ, Hu NW, Zhang T, Xu JT, Liu XG, (2006). Clonidine depresses LTP of C-fiber evoked field potentials in spinal dorsal horn via NO-cGMP pathway. Brain Res 1118: 58-65.
20. Hains BC, Everhart AW, Fullwood SD, Hulsebosch CE, (2002). Changes in serotonin, serotonin transporter expression and serotonin denervation supersensitivity: involvement in chronic central pain after spinal hemisection in the rat. Exp Neurol 175: 347-362.
21. 3 reduce hyperexcitability of dorsal horn neurons after chronic spinal cord hemisection injury in rat. Exp Brain Res 149: 174-186.
22. 2A/2C receptors. Neuropharmacology 51: 866-872.
23. Howe JR, Yaksh TL, (1982). Changes in sensitivity to intrathecal norepinephrine and serotonin after 6-hydroxydopamine (6-OHDA), 5,6-dihydroxytryptamine (5,6-DHT) or repeated monoamine administration. J Pharmacol Exp Ther 220: 311-321.
24. Ikeda H, Stark J, Fischer H, Wagner M, Drdla R, Jager T, et al,. (2006). Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science 312: 1659-1662.
25. Ikeda T, Ishida Y, Naono R, Takeda R, Abe H, Nakamura T, et al,. (2009). Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res 63: 42-46.
26. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM, (2004). Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311: 576-584.
27. Jones CK, Peters SC, Shannon HE, (2005). Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312: 726-732.
28. Kim SH, Chung JM, (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355-363.
29. King T, Rao S, Vanderah T, Chen Q, Vardanyan A, Porreca F, (2006). Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. J Pain 7: 513-520.
30. Lee YC, Chen PP, (2010). A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 11: 2813-2825.
31. Liu FY, Qu XX, Ding X, Cai J, Jiang H, Wan Y, et al,. (2010). Decrease in the descending inhibitory 5-HT system in rats with spinal nerve ligation. Brain Res 1330: 45-60.
32. Liu XG, Sandkühler J, (1995). Long-term potentiation of C-fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid receptor blockage. Neurosci Lett 191: 43-46.
33. Liu X, Sandkühler J, (1997). Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptors. J Neurophysiol 78: 1973-1982.
34. Mao J, Chen LL, (2000). Systemic lidocaine for neuropathic pain relief. Pain 87: 7-17.
35. Matthews EA, Dickenson AH, (2001). Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92: 235-246.
36. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
37. Millan MJ, (2002). Descending control of pain. Prog Neurobiol 66: 355-474.
38. 1A agonists and antagonists in rodents: relationship to algesiometric paradigm. Behav Brain Res 73: 69-77.
39. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al,. (2009). Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111: 60-72.
40. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M, (1985). Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24: 1211-1219.
41. Obata H, Saito S, Koizuka S, Nishikawa K, Goto F, (2005). The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 100: 1406-1410.
42. 2C receptor agonists in the rats with peripheral nerve injury. Eur J Pharmacol 567: 89-94.
43. Obata H, Kimura M, Nakajima K, Tobe M, Nishikawa K, Saito S, (2010). Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats. J Pharmacol Exp Ther 334: 1059-1065.
44. Ohnami S, Tanabe M, Shinohara S, Takasu K, Kato A, Ono H, (2011). Role of voltage-dependent calcium channel subtypes in spinal long-term potentiation of C-fiber-evoked field potentials. Pain 152: 623-631.
45. 2-adrenoceptors in enhancement of antinociceptive effect in diabetic mice. Eur J Pharmacol 592: 62-66.
46. Ramamoorthy S, Shippenberg TS, Jayanthi LD, (2011). Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol Ther 129: 220-238.
47. Randić M, Jiang MC, Cerne R, (1993). Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord. J Neurosci 13: 5228-5241.
48. Roudet C, Mouchet P, Feuerstein C, Savasta M, (1994). Normal distribution of alpha 2-adrenoceptors in the rat spinal cord and its modification after noradrenergic denervation: a quantitative autoradiographic study. J Neurosci Res 39: 319-329.
49. Rygh LJ, Kontinen VK, Suzuki R, Dickenson AH, (2000). Different increase in C-fibre evoked responses after nociceptive conditioning stimulation in sham-operated and neuropathic rats. Neurosci Lett 288: 99-102.
50. Rygh LJ, Suzuki R, Rahman W, Wong Y, Vonsy JL, Sandhu H, et al,. (2006). Local and descending circuits regulate long-term potentiation and zif268 expression in spinal neurons. Eur J Neurosci 24: 761-772.
51. Sandkühler J, (2009). Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 89: 707-758.
52. Sandkühler J, Liu X, (1998). Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury. Eur J Neurosci 10: 2476-2480.
53. 2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 84: 193-205.
54. Shin SW, Eisenach JC, (2004). Peripheral nerve injury sensitizes the response to visceral distension but not its inhibition by the antidepressant milnacipran. Anesthesiology 100: 671-675.
55. Sindrup SH, Otto M, Finnerup NB, Jensen TS, (2005). Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96: 399-409.
56. Suarez-Roca H, Quintero L, Arcaya JL, Maixner W, Rao SG, (2006). Stress-induced muscle and cutaneous hyperalgesia: differential effect of milnacipran. Physiol Behav 88: 82-87.
57. Suzuki T, Ueta K, Tamagaki S, Mashimo T, (2008). Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg 106: 1309-1315.
58. Svendsen F, Tjølsen A, Hole K, (1997). LTP of spinal Aβ and C-fibre evoked responses after electrical sciatic nerve stimulation. Neuroreport 10: 3427-3430.
59. Takano M, Takano Y, Yaksh TL, (1993). Release of calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal polypeptide (VIP) from rat spinal cord: modulation by alpha 2 agonists. Peptides 14: 371-378.
60. Tanabe M, Murakami H, Honda M, Ono H, (2006). Gabapentin depresses C-fiber-evoked field potentials in rat spinal dorsal horn only after induction of long-term potentiation. Exp Neurol 202: 280-286.
61. Vogel C, Mössner R, Gerlach M, Heinemann T, Murphy DL, Riederer P, et al,. (2003). Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci 23: 708-715.
62. Wallenstein S, Zucker CL, Fleiss JL, (1980). Some statistical methods useful in circulation research. Circ Res 47: 1-9.
63. Yang HW, Hu XD, Zhang HM, Xin WJ, Li MT, Zhang T, et al,. (2004). Roles of CaMKII, PKA, and PKC in the induction and maintenance of LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. J Neurophysiol 91: 1122-1133.
64. Yoshimura M, Furue H, (2006). Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci 101: 107-117.
65. Zhang HM, Zhou LJ, Hu XD, Hu NW, Zhang T, Liu XG, (2004). Acute nerve injury induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn of intact rat. Sheng Li Xue Bao 56: 591-596.
66. Zhang XC, Zhang YQ, Zhao ZQ, (2006). Different roles of two nitric oxide activated pathways in spinal long-term potentiation of C-fiber-evoked field potentials. Neuropharmacology 50: 748-754.